Science

Gustavo Viani: Should we rethink ADT omission in dose-escalated RT?

Gustavo Viani/sbradioterapia.com.br

Feb 11, 2025, 08:43

Gustavo Viani: Should we rethink ADT omission in dose-escalated RT?

Gustavo Viani, Associate Professor in the Department of Medical Imaging, Hematology, and Oncology at Hospital das Clínicas, shared an article by Krishnan R.Patel, et al. on X:

“Should we rethink ADT omission in dose-escalated RT?

Objective:

Evaluate whether ST-ADT + OS and biochemical control in IR-PCa.
Include all relevant randomized controlled trials (RCTs).

Methods:

Meta-analysis 7 RCTs (6,279),
Endpoints: OS (primary), biochemical failure (BF) and progression-free survival (bPFS) (secondary).

Results:

ST-ADT + OS (HR = 0.88, 5% survival gain at 10 y).
Biochemical control (HR = 0.50, p < 0.001).
Greater benefit with longer ADT duration & higher RT dose.

Conclusion:

ST-ADT survival and biochemical outcomes in IR-PCa.
Ongoing trials (NRG GU010) will refine selection.”

Gustavo Viani: Should we rethink ADT omission in dose-escalated RT?

The Benefit of Short-Term Androgen Deprivation Therapy with Radiotherapy for Intermediate-Risk Prostate Cancer.

Authors: Krishnan R. Patel, et al.

Gustavo Viani: Should we rethink ADT omission in dose-escalated RT?

androgen deprivation therapy cancer fight against cancer Global fight against cancer Gustavo Viani Hospital das Clínicas OncoDaily Oncology prostate cancer radiotherapy

Mesothelioma Guideline Updates from ASCO 2024: Key Advances in Diagnosis and Treatment

Oncologist Near Me - Lynn Schuchter: A Pioneering Leader in Cancer Care and Melanoma Research

NIH lowered the maximum indirect cost rate research institutions can charge the government to 15%

Stanley Tucci and Throat Cancer: How He Went Against, How He Survived, and More

Senator John Fetterman Responds to OncoDaily on Pediatric Oncology Funding